NHSA Revises 2024 NRDL Drug Information Based on Public Feedback
China’s National Healthcare Security Administration (NHSA) has announced revisions to the information about certain drugs...
Drug
Astellas’ Padcev and Keytruda Combo Cleared by NMPA for Urothelial Cancer
Japan-based Astellas Pharma Inc. (TYO: 4503) has announced marketing clearance by China’s National Medical Products...
HuidaGene Therapeutics Receives EMA Orphan Designation for HG004 Gene Therapy
Shanghai-based genome medicines specialist HuidaGene Therapeutics has announced a positive opinion from the European Medicines...
Mabwell’s 9MW2821 Granted Breakthrough Therapy Designation by CDE for Urothelial Carcinoma
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that the Center for Drug...
Kelun Pharmaceutical’s Generic Mulpleta Gains NMPA Approval in China
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced that it has received marketing...
Fujian Cosunter’s COVID-19 Therapy GST-HG171/ritonavir Approved in Macau
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced that its Category 1 product,...
Sanofi’s Sarclisa Gains NMPA Approval for Multiple Myeloma Treatment in China
French pharmaceutical giant Sanofi (NASDAQ: SNY) has announced that it has received marketing approval from...
Mirror Biologics and Merck KGaA Collaborate on Phase II Trial for Colorectal Cancer Immunotherapy
US-based Mirror Biologics, Inc., an off-the-shelf immunotherapy developer, has announced a clinical trial collaboration and...
Johnson & Johnson’s Posdinemab Receives FDA Fast Track Designation for Alzheimer’s Disease
US giant Johnson & Johnson (J&J, NYSE: JNJ) has announced that it has received Fast...
MSD’s Gardasil Vaccine Gains NMPA Approval for Use in Males Aged 9 to 26
US major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that it has received...
Bayer’s Nubeqa Seeks NMPA Approval for New Prostate Cancer Indication
Bayer AG (ETR: BAYN) has announced the submission of a supplemental new drug application (sNDA)...
Avenzo Therapeutics Licenses Duality Biologics’ EGFR/HER3 Bispecific ADC AVZO-1418/DB-1418
US-based oncology-focused biotech Avenzo Therapeutics, Inc. has signed a licensing agreement with Duality Biologics, an...
Insilico Medicine’s ISM5411 Shows Positive Results in Phase I Studies for Inflammatory Bowel Disease
China’s generative artificial intelligence (AI)-driven biotech, Insilico Medicine, has announced positive preliminary results from two...
Yiling Pharmaceutical Withdraws Clinical Filing for G201-Na in Assisted Reproduction
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced the withdrawal of its clinical filing...
Dizal’s Sunvozertinib Receives Priority Review from FDA for EGFR Exon 20 NSCLC
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced that its New Drug Application (NDA)...
CSPC Pharmaceutical Group Receives NMPA Approvals for ADC SYS6045 and PDE4B Inhibitor SYH2059
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received separate clinical...
Kelun-Biotech’s Anti-HER2 ADC A166 Receives NMPA Review for Expanded Indication
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) has announced that another indication approval filing for...
Hansoh and GSK’s HS-20093 Receives FDA Breakthrough Therapy Designation for Osteosarcoma
China-based Jiangsu Hansoh Pharmaceutical Co., Ltd (HKG: 3692) and its UK partner GSK plc (LON:...
Amgen’s Imdylltra Gains Conditional Approval in UK for Extensive-Stage Small Cell Lung Cancer
US biotech company Amgen (NASDAQ: AMGN) has received conditional approval from the UK’s Medicines and...
Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...